188 related articles for article (PubMed ID: 36348153)
1. Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries.
Rand LZ; Kesselheim AS
Pharmacoeconomics; 2022 Dec; 40(12):1131-1142. PubMed ID: 36348153
[TBL] [Abstract][Full Text] [Related]
2. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
[TBL] [Abstract][Full Text] [Related]
3. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
4. Estimated discounts generated by Medicare drug negotiation in 2026.
Hernandez I; Gabriel N; Dickson S
J Manag Care Spec Pharm; 2023 Aug; 29(8):868-872. PubMed ID: 37523318
[No Abstract] [Full Text] [Related]
5. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
6. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
7. The Constitutionality of Medicare Drug-Price Negotiation under the Takings Clause.
Bhargava R; Brown N; Kapczynski A; Kesselheim AS; Lim SY; Morten CJ
J Law Med Ethics; 2023; 51(4):961-971. PubMed ID: 38477274
[TBL] [Abstract][Full Text] [Related]
8. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.
Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
J Manag Care Spec Pharm; 2024 Jun; ():1-11. PubMed ID: 38905356
[TBL] [Abstract][Full Text] [Related]
9. Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions.
Sullivan SD
Value Health; 2023 Mar; 26(3):394-399. PubMed ID: 36503034
[TBL] [Abstract][Full Text] [Related]
10. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
11. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations.
DiStefano MJ; Levy JF; Odouard IC; Anderson GF
Value Health; 2023 Nov; 26(11):1618-1624. PubMed ID: 37689264
[TBL] [Abstract][Full Text] [Related]
12. German Pharmaceutical Pricing: Lessons for the United States.
Rodwin MA; Gerke S
Int J Health Serv; 2022 Jan; 52(1):146-158. PubMed ID: 34668806
[TBL] [Abstract][Full Text] [Related]
13. Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.
Egilman AC; Rome BN; Kesselheim AS
JAMA; 2023 Apr; 329(15):1283-1289. PubMed ID: 37071095
[TBL] [Abstract][Full Text] [Related]
14. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
[TBL] [Abstract][Full Text] [Related]
15. Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience.
Ludwig S; Dintsios CM
Value Health; 2016 Dec; 19(8):1016-1025. PubMed ID: 27987628
[TBL] [Abstract][Full Text] [Related]
16. Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016-2019 data.
Qureshi O; Ramachandran R; Ross JS
J Pharm Policy Pract; 2024; 17(1):2312374. PubMed ID: 38434725
[TBL] [Abstract][Full Text] [Related]
17. Negotiating antiretroviral drug prices: the experience of the Andean countries.
Seoane-Vazquez E; Rodriguez-Monguio R
Health Policy Plan; 2007 Mar; 22(2):63-72. PubMed ID: 17299024
[TBL] [Abstract][Full Text] [Related]
18. Drugs likely subject to Medicare negotiation, 2026-2028.
Dickson S; Hernandez I
J Manag Care Spec Pharm; 2023 Mar; 29(3):229-235. PubMed ID: 36840960
[No Abstract] [Full Text] [Related]
19. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
20. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.
Kanavos P; Ferrario A; Vandoros S; Anderson GF
Health Aff (Millwood); 2013 Apr; 32(4):753-61. PubMed ID: 23569056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
